BACKGROUND
Despite improved outcomes with immune checkpoint inhibitor (ICI) combinations in metastatic renal cell carcinoma (mRCC), reliable biologically-driven prognostic markers remain needed. The CHOMET study evaluated tumor ABCA1/ABCG1 expression and their association with systemic lipid parameters, nutritional sta...
G. C. Giudice, Hassan M. Abushukair, G. Mazzaschi et al.· The Oncologist· 0 citations
Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instabilit...
F. Flauto, G. Neola, Alessia Cimadamore et al.· The Oncologist· 0 citations
Abstract Background Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug–drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practi...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· The Oncologist· 0 citations
Immune checkpoint inhibitor (ICI)–based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCT...
A. A. Valsecchi, M. Maffezzoli, M. Cursano et al.· Cancer Metastasis Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.